Evidence map›Paper›PMID 33140048›Full record

ArticlebioRxiv : the preprint server for biology2020

Ethacridine inhibits SARS-CoV-2 by inactivating viral particles in cellular models.

Xiaoquan Li, Peter Lidsky, Yinghong Xiao, Chien-Ting Wu, Miguel GarciaKnight, Junjiao Yang, Tsuguhisa Nakayama, Jayakar V Nayak, Peter K Jackson, Raul Andino and 1 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 10 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Xiaoquan LiDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, California, USA.
Peter LidskyDepartment of Microbiology and Immunology, University of California, San Francisco, San Francisco, California, USA.
Yinghong XiaoDepartment of Microbiology and Immunology, University of California, San Francisco, San Francisco, California, USA.
Chien-Ting WuDepartment of Baxter Laboratory for Stem Cell Biology, Department of Microbiology & Immunology, Stanford University, California, USA.
Miguel GarciaKnightDepartment of Microbiology and Immunology, University of California, San Francisco, San Francisco, California, USA.
Junjiao YangDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, California, USA.
Tsuguhisa NakayamaDepartment of Otolaryngology-Head and Neck Surgery, Stanford University, Stanford, California, USA.
Jayakar V NayakDepartment of Otolaryngology-Head and Neck Surgery, Stanford University, Stanford, California, USA.
Peter K JacksonDepartment of Baxter Laboratory for Stem Cell Biology, Department of Microbiology & Immunology, Stanford University, California, USA.
Raul AndinoDepartment of Microbiology and Immunology, University of California, San Francisco, San Francisco, California, USA.
Xiaokun ShuDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, California, USA.
University of California, San Francisco · USStanford University · US

Funding

Unbiased Functional Characterization of Enterovirus-Host InteractionsP01AI091575 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ANDINO, RAUL · 2011 to 2015
$10.5M
RNA PROTEIN INTERACTIONS IN POLIOVIRUS REPLICATIONR01AI040085 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ANDINO, RAUL · 1998 to 2019
$5.8M
EQUIPMENT for Designing a new class of fluorescent reporters for imaging dynamic cell signaling in live animalsR35GM131766 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SHU, XIAOKUN · 2019 to 2025
$4.0M
RECOMBINANT PICORNAVIRUSES AS AIDS VACCINESR01AI036178 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ANDINO, RAUL · 1994 to 2011
$3.6M
RNA PROTEIN INTERACTIONS IN POLIOVIRUS REPLICATIONR21AI040085 · NIAID · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · PI ANDINO, RAUL · 1996 to 1996
–
NIAID NIH HHS N01 AI040085NIAID NIH HHS P01 AI091575NIAID NIH HHS R01 AI036178NIGMS NIH HHS R35 GM131766
6 · The paper itself

Abstract

SARS-CoV-2 is the coronavirus that causes the respiratory disease COVID-19, which is now the third-leading cause of death in the United States. The FDA has recently approved remdesivir, an inhibitor of SARS-CoV-2 replication, to treat COVID-19, though recent data from the WHO shows little to no benefit with use of this anti-viral agent. Here we report the discovery of ethacridine, a safe antiseptic use in humans, as a potent drug for use against SARS-CoV-2 (EC

Identifiers

PMID33140048
PMCPMC7605555
OpenAlexW3095573887

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.